Furthermore, DS-1594a·HCl is a potential differentiation therapeutic, as it effectively reversed differentiation blockade by reducing clonogenic potential and induced cellular differentiation in MLL-AF9 oncogene-evoked murine AML-like cells and patient-derived MLL1-r leukemia cells. This evidence concerns the gene KMT2A and acute myeloid leukemia.